Abstract
Long known for its anti-nociceptive effects, the opioid β-endorphin is also reported to have rewarding and reinforcing properties and to be involved in stress response. In this manuscript we summarize the present neurobiological and behavioral evidence regarding the role of β-endorphin in stress-related psychiatric disorders, depression and PTSD. There is existing data that support the importance of β-endorphin neurotransmission in mediating depression. As for PTSD, however, the data is thus far circumstantial. The studies described herein used diverse techniques, such as biochemical measurements of β-endorphin in various brain sites and behavioral monitoring, in two animal models of depression and PTSD. We suggest that the pathways for stress-related psychiatric disorders, depression and PTSD, converge to a common pathway in which β-endorphin is a modulating element of distress. This may occur its interaction with the mesolimbic monoaminergic system and also by its interesting effects on learning and memory. The possible involvement of β- endorphin in the process of stress-related psychiatric disorders, depression and PTSD, is discussed.
Keywords: Anxiety, depression, post-traumatic stress disorder (PTSD), opioids
Current Drug Targets
Title: The β-Endorphin Role in Stress-Related Psychiatric Disorders
Volume: 10 Issue: 11
Author(s): Avia Merenlender-Wagner, Yahav Dikshtein and Gal Yadid
Affiliation:
Keywords: Anxiety, depression, post-traumatic stress disorder (PTSD), opioids
Abstract: Long known for its anti-nociceptive effects, the opioid β-endorphin is also reported to have rewarding and reinforcing properties and to be involved in stress response. In this manuscript we summarize the present neurobiological and behavioral evidence regarding the role of β-endorphin in stress-related psychiatric disorders, depression and PTSD. There is existing data that support the importance of β-endorphin neurotransmission in mediating depression. As for PTSD, however, the data is thus far circumstantial. The studies described herein used diverse techniques, such as biochemical measurements of β-endorphin in various brain sites and behavioral monitoring, in two animal models of depression and PTSD. We suggest that the pathways for stress-related psychiatric disorders, depression and PTSD, converge to a common pathway in which β-endorphin is a modulating element of distress. This may occur its interaction with the mesolimbic monoaminergic system and also by its interesting effects on learning and memory. The possible involvement of β- endorphin in the process of stress-related psychiatric disorders, depression and PTSD, is discussed.
Export Options
About this article
Cite this article as:
Merenlender-Wagner Avia, Dikshtein Yahav and Yadid Gal, The β-Endorphin Role in Stress-Related Psychiatric Disorders, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735147
DOI https://dx.doi.org/10.2174/138945009789735147 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Photoreorganization of 2-methyl-3-(prop-2-ynyloxy)-4H-chromen-4-ones: Synthesis of 4-methylcoumarin Derivatives
Current Organic Synthesis Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry A Study of Pregnancy-Related Anxiety with Spiritual Health Among Cesarean and Vaginal Delivery
Current Women`s Health Reviews The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk)]
Current Pharmaceutical Design Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Physical Exercise for the Treatment of Neuropsychiatric Disturbances in Alzheimer’s Dementia: Possible Mechanisms, Current Evidence and Future Directions
Current Alzheimer Research GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders Statistical Identification of Gene-gene Interactions Triggered By Nonlinear Environmental Modulation
Current Genomics Recent Advances in the Synthesis of Naratriptan: An Anti-Migraine Drug
Mini-Reviews in Organic Chemistry Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters
Current Medicinal Chemistry Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology Compared Chemical Activity and Effects on Cell Viability of Various Antioxidant Compounds
Current Analytical Chemistry Metals, Toxicity and Oxidative Stress
Current Medicinal Chemistry Editorial: Management of Diabetes in Unique Populations
Current Diabetes Reviews Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies New Approaches in the Treatment of Overactive Bladder: Targeting Adrenergic Receptors and Neurokinin Receptors
Current Medicinal Chemistry - Central Nervous System Agents A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer s Disease, in Healthy Subjects and Patients
Current Clinical Pharmacology